Literature DB >> 31504324

Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.

Anne Marie Kerchberger1, Anandi N Sheth2, Christine D Angert3, C Christina Mehta3, Nathan A Summers2, Ighovwerha Ofotokun2, Deborah Gustafson4, Sheri D Weiser5, Anjali Sharma6, Adaora A Adimora7, Audrey L French8, Michael Augenbraun9, Jennifer Cocohoba10, Seble Kassaye11, Hector Bolivar12, Usha Govindarajulu13, Deborah Konkle-Parker14, Elizabeth T Golub15, Cecile D Lahiri2.   

Abstract

BACKGROUND: Integrase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is recommended for human immunodeficiency virus (HIV) management. Although studies have suggested associations between INSTIs and weight gain, women living with HIV (WLHIV) have been underrepresented in research. We evaluated the effect of switching or adding INSTIs among WLHIV.
METHODS: Women enrolled in the Women's Interagency HIV Study (WIHS) from 2006-2017 who switched to or added an INSTI to ART (SWAD group) were compared to women on non-INSTI ART (STAY group). Body weight, body mass index (BMI), percentage body fat (PBF), and waist, hip, arm, and thigh circumferences were measured 6-12 months before and 6-18 months after the INSTI switch/add in SWAD participants, with comparable measurement time points in STAY participants. Linear regression models compared changes over time by SWAD/STAY group, adjusted for age, race, WIHS site, education, income, smoking status, and baseline ART regimen.
RESULTS: We followed 1118 women (234 SWAD and 884 STAY) for a mean of 2.0 years (+/- 0.1 standard deviation [SD]; mean age 48.8 years, SD +/- 8.8); 61% were Black. On average, compared to the STAY group, the SWAD group experienced mean greater increases of 2.1 kg in body weight, 0.8 kg/m2 in BMI, 1.4% in PBF, and 2.0, 1.9, 0.6, and 1.0 cm in waist, hip, arm, and thigh circumference, respectively (all P values < .05). No differences in magnitudes of these changes were observed by INSTI type.
CONCLUSIONS: In WLHIV, a switch to INSTI was associated with significant increases in body weight, body circumferences, and fat percentages, compared to non-INSTI ART. The metabolic and other health effects of these changes deserve further investigation.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV positive; integrase strand transfer inhibitors; weight gain; women

Mesh:

Substances:

Year:  2020        PMID: 31504324      PMCID: PMC7384314          DOI: 10.1093/cid/ciz853

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association.

Authors:  Samuel Klein; David B Allison; Steven B Heymsfield; David E Kelley; Rudolph L Leibel; Cathy Nonas; Richard Kahn
Journal:  Am J Clin Nutr       Date:  2007-05       Impact factor: 7.045

2.  Trends in Obesity Among Adults in the United States, 2005 to 2014.

Authors:  Katherine M Flegal; Deanna Kruszon-Moran; Margaret D Carroll; Cheryl D Fryar; Cynthia L Ogden
Journal:  JAMA       Date:  2016-06-07       Impact factor: 56.272

Review 3.  Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.

Authors:  Tae Eun Park; Abdilahi Mohamed; Julie Kalabalik; Roopali Sharma
Journal:  Expert Rev Anti Infect Ther       Date:  2015-08-09       Impact factor: 5.091

4.  Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.

Authors:  Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

5.  Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat.

Authors:  Ian Janssen; Steven B Heymsfield; David B Allison; Donald P Kotler; Robert Ross
Journal:  Am J Clin Nutr       Date:  2002-04       Impact factor: 7.045

6.  Dolutegravir and weight gain: an unexpected bothering side effect?

Authors:  Amélie Menard; Line Meddeb; Herve Tissot-Dupont; Isabelle Ravaux; Catherine Dhiver; Saadia Mokhtari; Christelle Tomei; Philippe Brouqui; Philippe Colson; Andreas Stein
Journal:  AIDS       Date:  2017-06-19       Impact factor: 4.177

7.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

Review 8.  Aripiprazole: in adolescents with schizophrenia.

Authors:  Mark Sanford; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

9.  Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race.

Authors:  Priya Bhagwat; Ighovwerha Ofotokun; Grace A McComsey; Todd T Brown; Carlee Moser; Catherine A Sugar; Judith S Currier
Journal:  Open Forum Infect Dis       Date:  2018-11-16       Impact factor: 3.835

10.  Bioelectrical impedance analysis to estimate body composition, and change in adiposity, in overweight and obese adolescents: comparison with dual-energy x-ray absorptiometry.

Authors:  Ching S Wan; Leigh C Ward; Jocelyn Halim; Megan L Gow; Mandy Ho; Julie N Briody; Kelvin Leung; Chris T Cowell; Sarah P Garnett
Journal:  BMC Pediatr       Date:  2014-10-03       Impact factor: 2.125

View more
  31 in total

Review 1.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

2.  Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.

Authors:  Virginia A Triant; Mark J Siedner
Journal:  J Infect Dis       Date:  2020-02-03       Impact factor: 5.226

Review 3.  Metabolic Consequences of Antiretroviral Therapy.

Authors:  Caroline E Diggins; Samuel C Russo; Janet Lo
Journal:  Curr HIV/AIDS Rep       Date:  2022-03-17       Impact factor: 5.071

4.  Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.

Authors:  Jordan E Lake; Kunling Wu; Sara H Bares; Paula Debroy; Catherine Godfrey; John R Koethe; Grace A McComsey; Frank J Palella; Katherine Tassiopoulos; Kristine M Erlandson
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

5.  Changes in central adipose tissue after switching to integrase inhibitors.

Authors:  Paula Debroy; Han Feng; Hongyu Miao; Jovana Milic; Guido Ligabue; Stefano Draisci; Giulia Besutti; Federica Carli; Marianna Menozzi; Cristina Mussini; Giovanni Guaraldi; Jordan E Lake
Journal:  HIV Res Clin Pract       Date:  2021-01-18

6.  Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus.

Authors:  Archana Asundi; Alex Olson; Wenqing Jiang; Swati P Varshney; Laura F White; Manish Sagar; Nina H Lin
Journal:  AIDS Res Hum Retroviruses       Date:  2022-01-10       Impact factor: 2.205

7.  Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study.

Authors:  Jessie K Edwards; Stephen R Cole; Tiffany L Breger; Jacqueline E Rudolph; Lindsey M Filiatreau; Kate Buchacz; Elizabeth Humes; Peter F Rebeiro; Gypsyamber D'Souza; M John Gill; Michael J Silverberg; W Christopher Mathews; Michael A Horberg; Jennifer Thorne; H Irene Hall; Amy Justice; Vincent C Marconi; Viviane D Lima; Ronald J Bosch; Timothy R Sterling; Keri N Althoff; Richard D Moore; Michael Saag; Joseph J Eron
Journal:  Ann Intern Med       Date:  2021-07-06       Impact factor: 25.391

8.  Commentary on Lahiri et al. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.

Authors:  Francesca Macaluso; Deborah R Gustafson
Journal:  J AIDS HIV Treat       Date:  2021

9.  Systems Analysis of Gut Microbiome Influence on Metabolic Disease in HIV-Positive and High-Risk Populations.

Authors:  Abigail J S Armstrong; Kevin Quinn; Jennifer Fouquier; Sam X Li; Jennifer M Schneider; Nichole M Nusbacher; Katrina A Doenges; Suzanne Fiorillo; Tyson J Marden; Janine Higgins; Nichole Reisdorph; Thomas B Campbell; Brent E Palmer; Catherine A Lozupone
Journal:  mSystems       Date:  2021-05-18       Impact factor: 6.496

10.  Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort.

Authors:  Wei Li A Koay; Sahera Dirajlal-Fargo; Matthew E Levy; Paige Kulie; Anne Monroe; Amanda D Castel; Natella Y Rakhmanina
Journal:  Open Forum Infect Dis       Date:  2021-07-01       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.